A new study published in Clinical Gastroenterology and Hepatology confirms the real-world impact of ColoSense®, Geneoscopy’s FDA-approved multitarget stool RNA (mt-sRNA) test for colorectal cancer (CRC) screening. The modeling study, titled “Cost-effectiveness of novel noninvasive screening tests for colorectal neoplasia,” assessed five CRC screening strategies—including ColoSense, FIT, blood-based tests, and mt-sDNA tests—using a 10-year Markov model simulating disease progression in average-risk adults aged 45 and older.
At a real-world adherence rate of 60%, ColoSense significantly outperformed its peers in reducing CRC mortality:
- 14% fewer CRC deaths vs. FIT
- 19%–23% fewer than mt-sDNA tests
- 86% fewer than a blood-based test